311690.Kq
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company's capital structure is characterized by a debt-to-equity ratio of 0.19, indicating a relatively low reliance on debt financing. However, the company's liquidity position is assessed as medium, with a current ratio of 3.6, suggesting it has sufficient short-term assets to cover its liabilities, but with some room for improvement. The company's valuation snapshot reveals a negative return on equity of -44.75% and a negative return on assets of -33.18%, indicating poor profitability and asset utilization.
In terms of profitability, the company's operating income is significantly negative at -24.79 billion KRW, and its net income is also negative at -24.00 billion KRW, which is far below the industry median for profitability metrics. The company's gross profit of 698.91 million KRW is minimal compared to its total revenue of 3.69 billion KRW, suggesting high cost structures or low pricing power.
The company's revenue is concentrated in a single segment, as disclosed in its financials, with no significant geographic diversification reported. This concentration may expose the company to higher risks if demand in its primary market fluctuates or if regulatory changes impact its operations.
The company's growth trajectory is currently negative, with a significant decline in operating and net income. The outlook for the current fiscal year indicates a continuation of this trend, with no substantial improvement expected in the near term. The company's capital expenditure of -75.93 million KRW suggests minimal investment in new projects or expansion, which may limit its future growth potential.
The company's risk assessment highlights a medium liquidity risk, primarily due to its negative operating and free cash flows, which are -23.42 billion KRW and -20.07 billion KRW, respectively. The dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding. The company's negative net cash position after subtracting total debt is a key flag that may impact its financial stability.
Recent events, as disclosed in the company's financial filings, indicate ongoing challenges in achieving profitability and managing cash flows. The company has not reported any significant new product launches or strategic partnerships that could drive future growth. The lack of positive developments in recent filings suggests that the company may need to implement cost-cutting measures or seek additional financing to sustain operations.
- The company has a negative return on equity and return on assets, indicating poor profitability and asset utilization.
- The company's liquidity position is medium, with a current ratio of 3.6, suggesting it has sufficient short-term assets to cover its liabilities but with some room for improvement.
- The company's revenue is concentrated in a single segment, which may expose it to higher risks if demand in its primary market fluctuates.
- The company's growth trajectory is currently negative, with a significant decline in operating and net income, and no substantial improvement expected in the near term.
- The company's risk assessment highlights a medium liquidity risk due to its negative operating and free cash flows.
- **margin_outlook_rationale**: The company's gross margin is low, and the outlook for improvement is uncertain due to high cost structures and minimal gross profit.
- **rd_outlook_rationale**: The company's research and development outlook is not explicitly provided, but the lack of significant new product launches suggests limited R&D investment.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 311690.KQ Market data — financials · 2026-05-26